Pilot Projects Program

试点项目计划

基本信息

  • 批准号:
    10460365
  • 负责人:
  • 金额:
    $ 15.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-01 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

Pilot Projects Program - Abstract The Pilot Projects Program (PPP) is an integral component of the COBRE in Oxidants, Redox Balance and Stress Signaling and supports our mission to drive innovative redox-related basic and translational studies using the Center’s core resources and technologies. The overall goal of this program is to continue the significant momentum we have gained from the first two Phases of this COBRE by providing and prioritizing short-term funding for pilot studies that are designed to address important scientific questions in redox and signaling disciplines. We have incorporated innovative features of the PPP in this Phase III application, building on informatics tools and web resources developed and maintained by the South Carolina Clinical & Translational Institute (SCTR) that serve as CTSA-supported infrastructure, but provide a platform for electronic submission and review of applications and progress reports. The PPP will continue to provide and prioritize short-term funding through a competitive program which incorporates open solicitation, peer review and funding in three grant categories: Discovery: Attracting junior faculty without prior extramural funding to oxidants, redox balance and stress signaling research; New Direction: Enticing established investigators in other areas of biomedical research; and Feasibility: Enabling established redox investigators to explore an area that represents a significant departure from their currently funded work. The ultimate goal of the program is to provide adequate resources and training for pilot investigators to develop sufficient preliminary data to prepare a competitive extramural grant application that will directly utilize one or more of the COBRE cores. Our ultimate goal will be to use these funds to leverage additional funds and ideas that will expand participation and scientific competitiveness for the Center. Requests for applications will be solicited annually, four months in advance of the anticipated award date. Decisions related to the awarding of funds will be based on a rigorous and independent three-phase peer-review process that is modeled on the NIH system. The initial level of review will involve screening of proposals to verify that applications meet the eligibility criteria. The second will involve a panel of internal experts whose primary function will be to evaluate the scientific and technical merits of applications. A third level of review will be performed by the External Advisory Board. Applications will be scored using the NIH scale and prioritized according to four criteria: 1) Quality of the research (scientific merit, innovation, and impact); 2) Relevance to the mission of the Center and direct involvement of one or more COBRE Cores in the research plan; 3) qualifications of the research team to lead the research effort toward securing extramural funding and 4) stimulation of collaborative efforts with Center members. We plan to fund two new and/or continuation projects per year at $50,000 or $75,000 each for one to two years of support. We also envision that the PPP will enable investigators to form cooperative, interdisciplinary projects where sustainable studies can be turned into programmatic multi-investigator grant applications (e.g. U or P awards – we have been successful in garnering U awards, see Overall section) that will have a long-term impact on redox and cell signaling research at MUSC.
试点项目计划-摘要 试点项目计划(PPP)是COBRE在氧化剂,氧化还原平衡和 压力信号和支持我们的使命,以推动创新的氧化还原相关的基础和转化研究,使用 核心资源和技术。该计划的总体目标是继续重大的 我们从COBRE的前两个阶段中获得的动力, 资助旨在解决氧化还原和信号传导方面重要科学问题的试点研究 学科我们在第三期的申请中加入了公私营合作的创新特色, 由南卡罗来纳州临床和翻译部开发和维护的信息学工具和网络资源 SCTR作为CTSA支持的基础设施,但提供电子提交平台 以及审查申请和进度报告。PPP将继续提供并优先考虑短期 通过竞争性计划提供资金,该计划包括公开征集,同行评审和三个资助项目 资助类别:发现:在没有事先获得校外资助的情况下吸引初级教师研究氧化剂、氧化还原平衡 新方向:吸引生物医学其他领域的知名研究者 研究;和可行性:使既定的氧化还原研究人员探索一个领域,代表了一个 这与他们目前资助的工作有很大不同。该计划的最终目标是提供足够的 为试点调查员提供资源和培训,以编制充分的初步数据, 校外资助申请,将直接利用一个或多个COBRE核心。我们的最终目标是 利用这些资金来筹集更多的资金和想法,以扩大参与和科学研究, 中心的竞争力。申请将每年征求,提前四个月, 预计的颁奖日期。与资金发放有关的决定将根据严格的和 独立的三阶段同行评审过程,以NIH系统为模型。初步审查将 包括筛选建议书,以核实申请是否符合资格标准。第二个将涉及一个 内部专家小组,其主要职能是评估 应用.第三级审查将由外部咨询委员会进行。申请将被评分 使用NIH量表并根据四个标准进行优先排序:1)研究质量(科学价值, 创新和影响); 2)与中心使命的相关性以及一个或多个COBRE的直接参与 研究计划的核心; 3)研究团队的资格,以领导研究工作,以确保 校外资助和4)与中心成员的合作努力的刺激。我们计划资助两个新的 和(或)延续项目,每年各50 000美元或75 000美元,为期一至两年。我们也 设想公私伙伴关系将使研究人员能够在可持续的情况下形成合作的跨学科项目 研究可以转化为项目性多研究者资助申请(例如U或P奖-我们有 已成功获得U奖,见整体部分),这将对氧化还原和电池产生长期影响 MUSC的信号研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT T EBLEN其他文献

SCOTT T EBLEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT T EBLEN', 18)}}的其他基金

Pilot Projects Program
试点项目计划
  • 批准号:
    10674970
  • 财政年份:
    2021
  • 资助金额:
    $ 15.1万
  • 项目类别:
Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
MAP 激酶调节卵巢癌多药耐药性
  • 批准号:
    8038290
  • 财政年份:
    2009
  • 资助金额:
    $ 15.1万
  • 项目类别:
Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
MAP 激酶调节卵巢癌多药耐药性
  • 批准号:
    8211093
  • 财政年份:
    2009
  • 资助金额:
    $ 15.1万
  • 项目类别:
Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
MAP 激酶调节卵巢癌多药耐药性
  • 批准号:
    8433501
  • 财政年份:
    2009
  • 资助金额:
    $ 15.1万
  • 项目类别:
Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
MAP 激酶调节卵巢癌多药耐药性
  • 批准号:
    7736731
  • 财政年份:
    2009
  • 资助金额:
    $ 15.1万
  • 项目类别:
Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
MAP 激酶调节卵巢癌多药耐药性
  • 批准号:
    7822859
  • 财政年份:
    2009
  • 资助金额:
    $ 15.1万
  • 项目类别:
MAP KINASE NUCLEAR SIGNALING AND TRANSLOCATION
MAP 激酶核信号传导和转位
  • 批准号:
    2654922
  • 财政年份:
    1998
  • 资助金额:
    $ 15.1万
  • 项目类别:
MAP KINASE NUCLEAR SIGNALING AND TRANSLOCATION
MAP 激酶核信号传导和转位
  • 批准号:
    2021451
  • 财政年份:
    1997
  • 资助金额:
    $ 15.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了